how to switch from tirzepatide to semaglutide Semaglutide? how do you switch from

Proteomics data associated with this study are publicly available through the MassIVE repository (ID: MSV000095934)

GLP-1 receptor agonists should not be used in combination with DPP-4 inhibitors (such as sitagliptin or linagliptin), as both act on the incretin pathway

Sanofi Orexigen Therapeutics Amgen Johnson & Johnson Abbott Laboratories Takeda Pharmaceutical Company Zafgen Currax Pharmaceuticals Rhythm Pharmaceuticals Key Developments In September 2025, Eli Lilly announced plans to launch its experimental weight-loss pill, orforglipron, in India

The best choice depends on your individual health goals and preferences

Tangena JA, Marcombe S, Thammavong P, Chonephetsarath S, Somphong B, Sayteng K, et al